Nasus Pharma (NSRX) investor relations material

Company overview and business model

• Clinical-stage specialty pharmaceutical company developing intranasal powder-based drugs for emergency medical conditions, focusing on rapid drug absorption and user-friendly administration.

• Lead product NS002 is an intranasal epinephrine powder for anaphylaxis; NS001 is an intranasal naloxone powder for opioid overdose, with development paused pending partnerships.

• Proprietary powder-based intranasal (PBI) technology aims to outperform liquid-based solutions in speed and consistency of drug delivery.

• Additional pipeline includes preclinical programs for acute seizures, organophosphate poisoning, and intractable vomiting.

• No FDA-approved products to date; all revenues to date are from financing activities, not product sales.

Financial performance and metrics

• As of June 30, 2025, accumulated deficit was $13.9 million, with no product revenues and significant operating losses.

• Net loss for the six months ended June 30, 2025 was $1.25 million, up 44% from the prior year period.

• Cash and cash equivalents as of March 2, 2026 were approximately $16.2 million, following IPO and private placement proceeds.

• Research and development expenses increased 72% year-over-year for the six months ended June 30, 2025, reflecting increased clinical activity.

• Management expects current cash to fund operations through May 2027, but substantial additional funding will be required for commercialization.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises will fund clinical development of NS002, first-in-human studies for pipeline products, working capital, and general corporate purposes.

• February 2026 private placement raised $15 million gross, with potential for $17.6 million more from warrant exercises.